Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 7:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2209–2232 of 3,919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Prostate Cancer Clear all

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2037
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Metastatic Cancer, Prostate Cancer
Interventions: paricalcitol, immunoenzyme technique, laboratory biomarker analysis, dual x-ray absorptometry, quality-of-life assessment; Drug · Other · Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: Spectros Corporation; Industry
Eligibility: Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Cancer of the Prostate
Interventions: BHR-200 (0.36% transdermal 17β-estradiol gel), Placebo; Drug
Lead sponsor: BHR Pharma, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 12
States / cities: Tucson, Arizona • Aventura, Florida • Daytona Beach, Florida + 9 more

Conditions: Prostate Cancer
Interventions: Whole Body Non-Contrast MRI; Diagnostic Test
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Male only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Prostate Cancer, Liver Cancer, Breast Cancer, Colon Cancer, Lung Cancer
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Solid Tumors
Interventions: INCB057643, Gemcitabine, Paclitaxel, Rucaparib, Abiraterone, Ruxolitinib, Azacitidine; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 16
States / cities: Birmingham, Alabama • La Jolla, California • Denver, Colorado + 12 more

Conditions: Prostate Cancer, Castration Resistant Prostate Cancer, Pain, Prostatic Neoplasms
Interventions: cabozantinib, prednisone; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,028 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 77
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 73 more

Conditions: Prostate Cancer
Interventions: ASCENT; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 6
States / cities: Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 3 more

Conditions: Prostatic Neoplasms, Prostate Cancer
Interventions: Fulvestrant; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Stanford, California

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: Male only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Castration-resistant Prostate Cancer
Interventions: AR Blockade, Carotuximab; Drug
Lead sponsor: Edwin Posadas, MD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 3
States / cities: Duarte, California • Los Angeles, California • Salt Lake City, Utah

Conditions: Prostate Cancer
Interventions: Survivorship Care Plan, Enhanced Survivorship Care Plan; Other
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Interventions: Abemaciclib, Atezolizumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer Invasive, Prostate Cancer
Interventions: Audiovisual Intervention- Radiation Therapy Education, ASTRO Radiation Therapy for Breast or Prostate Cancer Brochure, Audiovisual Intervention- Cancer Clinical Trials Education, NCI Taking Part in Cancer Research Studies Brochure; Other
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Miami Beach, Florida • New York, New York

Conditions: Bone Metastases, Multiple Myeloma
Interventions: ExAblate MRfFUS, Sham; Device
Lead sponsor: InSightec; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 8
States / cities: La Jolla, California • Stanford, California • Boca Raton, Florida + 5 more

Conditions: Progressive Metastatic Castrate Resistant Prostate Cancer
Interventions: Tulmimetostat DL1 QD, Tulmimetostat DL2 QD, Tulmimetostat DL3 QD, Tulmimetostat Doses 1 or 2 QD, Tulmimetostat RP2D QD, JSB462 Dose 1 QD, JSB462 Dose 2 QD, JSB462 QD, Standard of Care (SoC); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 8
States / cities: Denver, Colorado • Jacksonville, Florida • Atlanta, Georgia + 5 more

Conditions: Renal Cell Cancer, Metastatic Castration Resistant Prostate Cancer
Interventions: Ciforadenant, Ciforadenant + atezolizumab; Drug
Lead sponsor: Corvus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 502 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 15
States / cities: Tucson, Arizona • San Francisco, California • Stanford, California + 11 more

Conditions: Pain, Metastatic Breast Cancer, Prostate Cancer, Colorectal Cancer
Interventions: Quell, Sham Quell; Device
Lead sponsor: Scripps Translational Science Institute; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 40 Years to 95 Years · Male only
Enrollment: 60 participants
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: sargramostim, ketoconazole, therapeutic hydrocortisone; Biological · Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: Up to 120 Years · Male only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Male only
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Prostate Cancer, Quality of Life
Interventions: Quality of Life Questionnaires; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Male only
Enrollment: 959 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: docetaxel, Blood draws; Drug · Other
Lead sponsor: Saladax Biomedical, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 20
States / cities: Beaver, Pennsylvania • Bethel Park, Pennsylvania • Farrell, Pennsylvania + 13 more

Search by objective public record fields.

Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue

Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases

Imaging of Residual Tumor During Prostatectomy

Maintaining Suppression of Testosterone With Transdermal Estradiol Gel

Non-contrast MR Imaging for Whole Body Cancer Detection and Characterization

Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

A Survivorship Care Plan and Embedded Navigation Tool

Fulvestrant in Hormone Refractory Prostate Cancer

Changes in Brown Adipose Tissue Activity In Men Receiving Androgen Deprivation Therapy for Prostate Cancer

Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate Canc

Enhancing Survivorship Care Planning for Patients With Localized Prostate Cancer Using A Couple-focused Web-based Tailored Symptom Self-management Program

Abemaciclib With or Without Atezolizumab for mCRPC

AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc

ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers

Quell Opioid Reduction and Pain Relief in Patients With Cancer

PRISM Study: Prostate Recurrence Detection Using Imaging With PSMA PET/MRI Post-high Intensity Focused Ultrasound

Ketoconazole, Hydrocortisone, and GM-CSF in Treating Patients With Progressive Prostate Cancer After Hormone Therapy

Evaluation of Neuroendocrine Differentiation as a Potential Mechanism of Tumor Recurrence Following Radiotherapy

Clinical and Quality of Life Outcomes After Open or Robotic-Assisted Laparoscopic Radical Prostatectomy

Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients